Oncoceutics expands DRD2 research collaborations with NIH

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Oncoceutics Inc. announced research collaborations with various groups within the NIH to study DRD2 as a novel therapeutic target in oncology.

DRD2, a member of the dopamine receptor family that is part of the G protein-coupled receptor superfamily, is a well-known drug target but one that has not been explored previously as a target for clinical oncology. As a result of recent work by Oncoceutics with its cancer drug candidate called ONC201 that selectively antagonizes DRD2 and is in phase II clinical trials, Oncoceutics has generated interest by multiple institutions within the NIH to study basic, translational, and clinical research opportunities for both ONC201 and other related drug candidates called imipridones.

In addition to Oncoceutics’ relationship with NCI, the company has recently expanded its collaborations throughout NIH institutions to include:

  • Preclinical and clinical evaluation of ONC201 in advanced breast and endometrial cancers by a team led by Stanley Lipkowitz, chief of Women’s Malignancies Branch at the NCI;

  • DRD2 receptor pharmacology and signaling studies of imipridones by the laboratory of David Sibley, chief of the Molecular Neuropharmacology Section at the National Institute of Neurological Disorders and Stroke; and

  • Translational evaluation of ONC206 (a related drug candidate also under development by Oncoceutics) as a potent and selective DRD2 antagonist for neuro-oncology by a team of investigators led by Mark Gilbert, at the Neuro-oncology branch that itself is a collaboration between NCI and NINDS.

NCI also continues to support clinical investigation of ONC201 as a single agent in recurrent glioblastoma through a small business innovation research grant, and discussions are underway with the NCI regarding the clinical evaluation of ONC201 in combination with targeted agents.

“The unique pharmacology and mechanism of action associated with ONC201 and other imipridones that has come to light in the past year opens up an exciting new arena for basic and clinical investigations,” said Joshua Allen, vice president of research and development at Oncoceutics. “We are delighted to work with these expert multi-disciplinary teams to continue to elucidate the elegant and complex basic biology of this receptor, how imipridones uniquely target this receptor, and how we assimilate this information to maximize the clinical benefit offered by imipridones to cancer patients.”

“True medical breakthroughs in oncology and other diseases are driven by the introduction of novel classes of therapeutic targets,” said Keith Flaherty, director of Developmental Therapeutics at Massachusetts General Hospital.

“We have seen this in recent history with oncogene targeted therapies that have been followed by immune checkpoint inhibitors, and the question is what realm of therapeutic targets will be the next to drive a quantum leap. G protein-coupled receptors are a befitting family of druggable receptors that are dysregulated in cancer and control broadly important signal transduction pathways.”

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login